Anti-hepatitis Agents

Random Miscellaneous Quiz

Can you name the Anti-hepatitis Agents?

Quiz not verified by Sporcle

embed
 plays        
How to Play
HintAnswer
Group MOA cont. (3) Protein kinase (activated by dsRNA): phosphorylates/inhibits eIF-2, therefore blocking PRO synthesis
SE: Flu-like symptoms (fever, chills, myalgias, malaise). Neurotoxicity, myelosuppression, fatigue (chronic use). Transient hepatic enzyme elevation.
Use: Improve therapeutic response in pts (>18 yo) w/ HCV genotype 1 when combined w/ IFN/ribavirin
Tenofovir Class
Use: HBV treatment adults only
P-kinetics: Oral bioavailability increased with high-fat meal, decreased with antacid.
Contraindications: Hepatic decompensation, autoimmune dz, cardiac arrhythmia, pregnancy
Group MOA: 3 major enzymes are activated by IFN-JNK/STAT signaling pathway: (1) 2',5' oligo A synthase: produces 2'5' oligo A.
SE: Dose-dependent hemolytic anemia. Depression, fatigue, irritability, nausea, insomnia.
Adefovir dipivoxil (Hepsera) Class
MOA: Serine protease inhibitors. Bind to inhibit HCV non-structural protein NS3
PEG-IFN α-2a/2b class
Telbivudine (Tyzeka) Class
MOA: A prodrug of adefovir (adenosine analogue). Slows suppression of HBV DNA; least seroconversion
Lamivudine (3TC, Heptovir) Class
P-kinetics: Natural. SC or IM
Group MOA cont. (2) Ribonuclease L (activated by 2'5' oligo A): degrades mRNA.
Use: Effective suppression of HBV DNA, normalization of ALT & reducing HBeAg. Adults only
MOA: A prodrug (a guanosine nucleoside analogue). Phosphorylated by host cell enzymes; inhibits viral RNA-dependent polymerases.
Boceprevir Class
MOA: A thymidine analog
SE: Nephrotoxicity (at high doses). Potential mitochondrial DNA toxicity
Contraindications: Pts w/ uncorrected anemia, ESRD, preggo. Teratogenic: avoid pregnancy for > 6 mos thereafter
MOA: An adenosine analogue. Structurally similar to adefovir.
P-kinetics: Lipophilic (pivoxil) moiety enhances oral bioavailability.
HintAnswer
P-kinetics: Prolonged intracellular half-life in HBV (than in HIV). Rapid oral absorption; eliminated unchanged. Used at lower doses for hepatitis than for AIDS.
P-kinetics: Slower clearance (less frequent dosing). Dosage adjustment is needed in renal dysfunction
Telaprevir Class
Drug MOA: PEG = polyethylene glycol
MOA: A guanisine analog. Inhibits all 3 functions of HBV RNA-dependent DNA polymerase (base priming, reverse transcription of the -strand, synthesis of the + strand of HBV DNA.
Use: Lamivudine-resistant HBV. Adults only
Group MOA cont: Associated with mitochondrial DNA toxicity (by inhibiting DNA polymerase gamma)
P-kinetics: Oral (TID). P450 substrates (potential rx interactions)
IFN alfacon-1 class
Group P-kinetics: Pills once a day for a year or longer
Group MOA: Competively inhibit HBV DNA polymerase +/- incorporate into viral DNA causing chain termination. Phosphorylated to active forms intracellularly by cellular kinases.
IFN α-2a/2b class
Entecavir (Baraclude) Class
P-kinetics: Higher rate of complete response & less resistance vs. adefovir
IFN α-2b Class
SE: HA, fatigue, nausea. Potential mitochondrial toxicity (lactic acidosis & hepatic steatosis)
MOA: A cytosine analogue
Use: HBV: Safer for pts w/ decompensated liver dz. For both adults & peds
P-kinetics: Synthetic (consensus). SC
Use: The most potent anti-HBV agent. Adults only
SE: Increased pancreatitis in HIV/HBV pts. Emergence of resistance (mutations of DNA polymerase)
SE: Anemia, neutropenia, dysgeusia, skin rash (esp. telaprevir), increased QT intervals (telaprevir)
PEG-IFN α-2a Class
P-kinetics: Clinical resistance is rare. Oral bioavailability decreased by food (taken w/ empty stomach). Renal elimination (serum concentration increased w/ altered kidney activit
P-kinetics:Oral bioavailability not affected by food. Emergence of resistance in long term use.

Friend Scores


  Player Best Score Plays Last Played
You You haven't played this game yet.

You Might Also Like...

Show Comments

Extras